588
Participants
Start Date
August 31, 2012
Primary Completion Date
July 31, 2013
Study Completion Date
July 31, 2013
Olmesartan
10 mg, 20 mg, 40 mg capsules
Placebo
Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
LCZ696
100 mg, 200 mg tablets
Novartis Investigative Site, Taipei
Novartis Investigative Site, Taipei
Novartis Investigative Site, Changhua
Novartis Investigative Site, Kaohsiung City
Novartis Investigative Site, Manila
Novartis Investigative Site, Quezon City
Novartis Investigative Site, Quezon City
Novartis Investigative Site, Quezon City
Novartis Investigative Site, Valenzuela
Novartis Investigative Site, Taipei
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Incheon
Novartis Investigative Site, Taichung
Novartis Investigative Site, Taichung
Novartis Investigative Site, Chiang Mai
Novartis Investigative Site, Beijing
Novartis Investigative Site, Shenyang
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Suzhou
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Chongqing
Novartis Investigative Site, Changsha
Novartis Investigative Site, Xi’an
Novartis Investigative Site, Hong Kong
Novartis Investigative Site, Hong Kong
Novartis Investigative Site, Hong Kong
Novartis Investigative Site, Taipei
Novartis Investigative Site, Tōon
Novartis Investigative Site, Chikushi-gun
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Asahikawa
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Kyōtanabe
Novartis Investigative Site, Osaka
Novartis Investigative Site, Suita
Novartis Investigative Site, Toyonaka
Novartis Investigative Site, Fujimino
Novartis Investigative Site, Hiki-Gun
Novartis Investigative Site, Koshigaya
Novartis Investigative Site, Saitama
Novartis Investigative Site, Tokorozawa
Novartis Investigative Site, Edogawa-ku
Novartis Investigative Site, Edogawa-ku
Novartis Investigative Site, Hachiōji
Novartis Investigative Site, Hachiōji
Novartis Investigative Site, Katsushika-ku
Novartis Investigative Site, Kiyose
Novartis Investigative Site, Kunitachi
Novartis Investigative Site, Meguro-ku
Novartis Investigative Site, Minato-ku
Novartis Investigative Site, Minato-ku
Novartis Investigative Site, Shibuya-ku
Novartis Investigative Site, Shinagawa-ku
Novartis Investigative Site, Tachikawa
Novartis Investigative Site, Taitō City
Novartis Investigative Site, Toshima-ku
Novartis Investigative Site, Bucheon-si
Novartis Investigative Site, Goyang-si
Novartis Investigative Site, Seongnam-si
Novartis Investigative Site, Jeonju
Novartis Investigative Site, Koyang
Novartis Investigative Site, Seoul
Novartis Investigative Site, Daegu
Novartis Investigative Site, Daejeon
Novartis Investigative Site, Incheon
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY